Cardiovascular disease in patients with osteogenesis imperfecta — a nationwide, register-based cohort study
Open Access
- 1 December 2016
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 225, 250-257
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- AstraZeneca
- National Park Service
- GlaxoSmithKline
- UCB
- Amgen
- Novo Nordisk
- Eli Lilly and Company
- Shire
- Merck
This publication has 23 references indexed in Scilit:
- Cardiopulmonary dysfunction in the Osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanismsHuman Molecular Genetics, 2012
- The Danish National Patient RegisterScandinavian Journal of Public Health, 2011
- The Danish Civil Registration SystemScandinavian Journal of Public Health, 2011
- The Danish National Prescription RegistryScandinavian Journal of Public Health, 2011
- Cardiovascular abnormalities in adults with osteogenesis imperfectaAmerican Heart Journal, 2011
- Impairment of diastolic function in adult patients affected by osteogenesis imperfecta clinically asymptomatic for cardiac disease: Casuality or causality?International Journal of Cardiology, 2009
- The role of type I collagen in aortic wall strength with a homotrimeric [α1(I)]3 collagen mouse modelJournal of Vascular Surgery, 2001
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Structure of chordae tendineae in the left ventricle of the human heartJournal of Anatomy, 1998
- Osteogenesis imperfecta: a genetic, radiological, and epidemiological studyClinical Genetics, 1989